Moreover, treatment with minocycline (a tetracycline derivative) an inhibitor of circulating metalloproteinases, reduced MMP-9 activity, restored the synaptic development in Fmr1 KO mice, and improved aberrant behavior of Fmr1 KO mice and FXS patients16–18. Here, MMP9 is linked to fragile X syndrome.